April 24, 2024

• 

[THE INVESTOR] Hanmi Pharmaceutical’s anti-cancer treatment poziotinib’s outlook for commercialization is brightening, said Daishin Securities on Sept. 7, maintaining a “buy” recommendation and 620,000 won (US$551.85) target price. 

According to interim data poziotinib showed efficacy with 58 percent objective response rate in 40 patients with mutations in exon 20 of epidermal growth factor receptor. The rate reached 50 percent in 12 patients with mutations in exon 20 of human epidermal growth factor receptor 2, said analyst Hong Ga-hye.

In the fourth quarter, its partner Spectrum Pharmaceuticals will seek approval of the US Food and Drug Administration for poziotinib to be designated as a breakthrough therapy. Once it gets approval the candidate could be rolled out as soon as the second-phase clinical trials are completed in 2021 at the latest, forecast the analyst. 

By Hwang You-mee (glamazon@heraldcorp.com)